Find your next paid study

Anusha KalbasiNCT04119024

~$10 – $7,500

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translation…

Healthy VolunteerProstate CancerHead and Neck Cancer+10 more

Washington University School of MedicineNCT04354064

~$10 – $750

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung can…

Breast CarcinomaColorectal CarcinomaLung Non-Small Cell Carcinoma+2 more

Wake Forest University Health SciencesNCT06418204

~$10 – $750

Phase 2

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Advanced Melanoma

Eikon TherapeuticsNCT06697301

Metastatic MelanomaBRAF Gene Mutation

A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib or Encorafenib/Binimetinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition

This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresecta…

~$10 – $7,500

Rina PlattnerNCT04903119

Solid Tumor, AdultTriple Negative Breast CancerColorectal Cancer+6 more

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Admini…

BioEclipse TherapeuticsNCT04282044

Observational

Pilot Study Assessment of Bone Mineral Density Changes During Treatment With Anti-PD-1 Immunotherapy Agents

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from…

Breast Cancer (Triple Negative Breast Cancer (TNBC))Renal Cell Carcinoma (Kidney Cancer)Melanoma (Skin Cancer)+5 more

Jessica Mezzanotte SharpeNCT07555210

~$10 – $7,500

Solid TumorSmall Cell and Non-small Cell Lung CancerHead and Neck Cancer+6 more

Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors

The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through bl…

Rapa Therapeutics LLCNCT05144698

A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients With Stage IIB-IIIC Melanoma

This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, hist…

Melanoma

MelanomaMelanoma Stage IIIMelanoma (Skin)+1 more

~$10 – $1,125

John KirkwoodNCT06599619

Phase 2

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.

University of California, IrvineNCT06771544

~$10 – $6,250

Advanced Colorectal CarcinomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid Neoplasm+13 more

Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients With Advanced Malignancies Being Treated With Standard of Care Checkpoint Inhibitor-Based Therapy

This phase I clinical trial tests the immune effects of fermented wheat germ in patients with advanced solid tumor cancers who are being treated with standard …

~$10 – $6,250

Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma

This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get so…

Metastatic Melanoma